MKS Instruments Inc (MKSI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at MKS Instruments Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 28 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 297.50 $ — 59% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
Uses AIMKS Inc. (vormals MKS Instruments) verkauft keine KI-Produkte; das Kerngeschäft — Präzisionsinstrumente, Subsysteme und Prozesschemie für die Halbleiterfertigung — profitiert nur als Endmarkt-Zulieferer vom KI-Chip-Boom (die 10-K-Berichte nennen „AI-related demand“ als Nachfragetreiber im Halbleiter- und Elektronikgeschäft, das laut Kriterienkatalog allein noch kein „verkauft“ begründet). Operativ belegt der Geschäftsbericht (10-K) 2025 einen frühen, begrenzten internen KI-Einsatz („We are in the early stages of integrating AI into our business and operational processes“) — damit greift Rang 3 „nutzt“. Ein konkretes KI-Geschäftsrisiko fürs eigene Modell (Rang 2 „bedroht“) wird nicht als existenziell dargestellt, eine KI-Umsatzquelle (Rang 1 „verkauft“) fehlt.
View the full file — quotes, sources, reviewed filings
„We are in the early stages of integrating AI into our business and operational processes and continue to explore new uses. AI technologies are complex and rapidly evolving."
Wir befinden uns in einem frühen Stadium der Integration von KI in unsere Geschäfts- und Betriebsprozesse und erkunden weiterhin neue Einsatzmöglichkeiten. KI-Technologien sind komplex und entwickeln sich rasch weiter.
„Due in part to these demand shifts, including AI-related demand and trade restrictions, our semiconductor market revenue sequentially increased 13% in 2025, sequentially increased 1% in 2024, but sequentially decreased 28% in 2023."
Teilweise aufgrund dieser Nachfrageverschiebungen — einschließlich der KI-bezogenen Nachfrage und der Handelsbeschränkungen — stieg unser Halbleiter-Umsatz 2025 um 13 Prozent und 2024 um 1 Prozent, ging 2023 aber um 28 Prozent zurück.
Filings Reviewed: 10-Q 2026-05-07 · 10-Q 2025-11-06 · 10-Q 2025-08-07 · 10-Q 2025-05-08 · 10-K 2026-02-24 · 10-K 2025-02-25
Rated on July 10, 2026 · How the Rating Is Built
What the Earnings Calls Reveal
Positive delivers reliablyAcross ten calls from fiscal 2023-Q4 through 2026-Q1, the MKS management team led by CEO John Lee shows an unusually reliable pattern: quarterly guidance was met or beaten in all nine verifiable cases, mostly at the upper end of the range. The only reversal - the second-half 2024 recovery expectation was temporarily withdrawn on the 2024-Q2 call - was explained openly and ultimately delivered anyway. Deleveraging, tariff mitigation and the CFO succession all played out as announced; still open are the gross margin target of above 47 percent and the long-term leverage target.
10 calls reviewed, 2023-Q4 through 2026-Q1 · As of August 2, 2026
Guidance met or beaten nine quarters in a row
From 2024-Q1 through 2026-Q1, revenue landed at least at the midpoint of the company's own guidance in every single quarter, usually at or above the high end: 2024-Q1 868 million dollars (midpoint 840), 2025-Q2 973 million (above the 965 high end), 2026-Q1 1.08 billion (high end of the range). Earnings per share exceeded the high end in 2024-Q1, 2024-Q2, 2024-Q3, 2025-Q1 and 2026-Q1. Management deliberately guides only one quarter out and sets the bar visibly conservative - a pattern that stayed stable over the entire period.
The one 2024 reversal: openly explained and delivered after all
On the 2023-Q4 and 2024-Q1 calls, management pointed to second-half 2024 revenue slightly above the first half. On the 2024-Q2 call this was cut back to 'roughly in line' - with a clear reason: the industry recovery was pushing out, they were 'bouncing along the bottom a little longer than we thought'. On the 2024-Q3 call the expectation was raised again to low-to-mid single digit growth, and that is exactly what happened: the second half came in about 4 percent above the first. A zigzag in expectations, but no broken promise - and communicated transparently throughout.
Deleveraging as announced, but target stated inconsistently
The pledge repeated since 2023-Q4 to put excess free cash flow into debt reduction was consistently honored: 426 million dollars of voluntary prepayments in 2024, 400 million in 2025, over 1 billion in total since February 2024; net leverage fell from 4.7x (2023-Q4) to 3.5x (2026-Q1). The only wrinkle is the target itself: on the 2024-Q4 call CFO Mayampurath named '2x net' as the goal, while on the 2025-Q3 call, asked about '2x by 2027', he confirmed '2.5' as the net target - without explaining the shift. No date for the target was ever promised.
Tariffs: estimate slightly missed, mitigation delivered
On the 2025-Q1 call management sized the tariff hit to gross margin at 'up to 100 basis points'; the actual figure in 2025-Q2 was 115 basis points - a miss the team acknowledged itself on the following call. After that, the announced reduction ran on schedule: 80 basis points in 2025-Q3, about 50 from 2025-Q4 with dollar-for-dollar offset, 30 to 40 in 2026-Q1. The commitment given on the 2025-Q1 call to a long-term gross margin above 47 percent is not yet fulfilled: 2025 ended at 46.7 percent and 2026-Q1 reached exactly 47.0 percent - the 'plus' is still pending, but the target was reaffirmed on every call.
Consistent non-answers rather than evasion
Questions about full-year WFE forecasts and the timing of the NAND recovery were as a rule not answered with numbers by CEO Lee across all calls ('If I could do that, I don't have to do this job', 2025-Q1) - a stated policy, not situational dodging, and it was never broken. On the AI revenue share, disclosure actually improved measurably: in 2024-Q4 a breakdown was still called 'difficult', but from 2025-Q3 management gave concrete figures (AI share of chemistry revenue from 5 percent in 2024 to 10 percent in 2025, heading toward 15 percent in 2026-Q1). We found no repeated evasion of the same concrete question.
Management promises
-
2023-Q4 kept
Reach 55 million dollars of Atotech cost synergies by the end of 2024-Q2.
Reported as exceeded already on the 2024-Q1 call - one quarter earlier than promised and at the early end of the original 18-to-36-month window.
-
2023-Q4 kept
Name a successor for retiring CFO Seth Bagshaw and keep the market updated.
Status update on every interim call; on the 2024-Q3 call Ram Mayampurath was introduced as the new CFO (start October 2024).
-
2024-Q1 kept
Second-half 2024 revenue slightly above the first half.
Temporarily cut to 'in line' on the 2024-Q2 call, raised again on the 2024-Q3 call; H2 actually came in about 4 percent above H1 - the original statement ended up true.
-
2024-Q4 open
Keep reducing net debt with excess free cash flow, target 2x net.
The paydown is demonstrably on track (4.3x at end of 2024 to 3.5x in 2026-Q1, over 1 billion dollars repaid since February 2024); however, the target itself was stated as 2.5x instead of 2x on the 2025-Q3 call, and no date was ever promised.
-
2025-Q1 open
Long-term gross margin above 47 percent despite tariff costs.
2025 ended at 46.7 percent (tariffs, equipment mix), 2026-Q1 reached 47.0 percent again and the Q2 guide holds that level; the 'plus' is still outstanding, and the target is reaffirmed on every call.
-
2025-Q3 kept
Offset tariff costs dollar for dollar from 2025-Q4, residual gross margin impact around 50 basis points.
Confirmed as largely achieved on the 2025-Q4 call (residual around 50 basis points), down to 30 to 40 basis points in 2026-Q1 - reduced as announced.
Based on public earnings call transcripts. Reviewed: 10 transcripts 2023-Q4 through 2026-Q1.
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 3.5% failed
- More than 10% revenue growth is expected for the coming year 15.1% passed
- Share count grows by less than 3% a year 4.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 22.3% failed
- Gross margin at 40% or higher and without meaningful erosion 40.5% failed
- Goodwill from acquisitions does not grow faster than revenue 29.3% passed
- Net debt below twice EBITDA 4.7 x EBITDA failed
- Operating cash flow covers the profits of the last three years 2,848 m passed
- Return on capital at 15% or higher, or up versus two years ago 7.2% passed
- Insiders hold at least 10% or are net buyers 0.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 38.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 11.78 | 11.06 – 12.36 | 4,817 | 49.5% | 13 |
| 12/31/2027 | 15.45 | 13.80 – 17.62 | 5,603 | 31.1% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 2.93 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.34 | – | 934 | 4.70 | 9.70 | 176 | 125 |
| 2025: Q1 | 0.77 | 245.10 | 936 | 7.80 | 5.60 | 141 | 123 |
| 2025: Q2 | 0.92 | 170.00 | 973 | 9.70 | 6.40 | 165 | 136 |
| 2025: Q3 | 1.09 | 19.40 | 988 | 10.30 | 7.50 | 197 | 146 |
| 2025: Q4 | 1.57 | 17.10 | 1,033 | 10.60 | 10.40 | 142 | 91 |
| 2026: Q1 | 1.18 | 53.80 | 1,078 | 15.20 | 7.80 | 53 | 28 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,295 | 157 | 105 | 1.94 | 180 | 1,242 | 2,212 |
| 2017 | 1,916 | 407 | 339 | 6.16 | 355 | 1,589 | 2,414 |
| 2018 | 2,075 | 494 | 393 | 7.14 | 414 | 1,873 | 2,614 |
| 2019 | 1,900 | 220 | 140 | 2.55 | 245 | 2,023 | 3,416 |
| 2020 | 2,330 | 454 | 350 | 6.33 | 513 | 2,361 | 3,904 |
| 2021 | 2,950 | 699 | 551 | 9.89 | 640 | 2,887 | 4,540 |
| 2022 | 3,547 | 617 | 333 | 5.56 | 529 | 4,483 | 11,495 |
| 2023 | 3,622 | -1,554 | -1,841 | -27.56 | 319 | 2,472 | 9,118 |
| 2024 | 3,586 | 498 | 190 | 2.81 | 528 | 2,322 | 8,590 |
| 2025 | 3,931 | 565 | 295 | 4.36 | 645 | 2,719 | 8,796 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
MKS Inc. bietet grundlegende Technologielösungen für die Halbleiterfertigung, Elektronik und Packaging sowie spezielle industrielle Anwendungen in den USA, China, Südkorea, Japan, Taiwan, Singapur und international an.
| Employees | 10,200 |
|---|---|
| Headquarters | Andover, MA |
| Address | 2 Tech Drive, 01810 Andover, United States |
| Phone | 978 645 5500 |
| Website | mks.com |
| IPO Date | 26. Mar 1999 |
| ISIN | US55306N1046 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John T. C. Lee Ph.D. | President, CEO & Director | 1963 |
| Ramakumar Mayampurath | Executive VP & CFO | 1964 |
| James Alan Schreiner | Executive VP & COO | 1962 |
| David Philip Henry | EVP, Global Strategic Marketing & GM of Materials Solutions Division | 1972 |
| Michelle M. McCarthy | VP & Chief Accounting Officer | 1981 |
| Madhuri A. Andrews | Executive VP & Chief Information Officer | 1967 |
| Paretosh Misra C.F.A., Ph.D. | Vice President of Investor Relations | – |
| Renee M. Donlan | Executive VP, General Counsel & Chief Compliance Officer | – |
| Sally Ann Bouley | Executive VP & Chief Human Resources Officer | – |
| Eric Robert Taranto | Executive VP & GM of Vacuum Solutions Division | 1968 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.